New crown specific drugs, upgraded vaccines... a large number of innovative results intensively unveiled
Exploring health at the Service Trade Fair (Health Through Train (64th stop))
On September 3, the anti-epidemic products of Sinopharm's China Biological Exhibition Area attracted attention in the Health and Sanitation Services Pavilion in the Shougang Park Exhibition Area of the 2021 Service Trade Fair.
Photo by our reporter Wang Meihua
On September 4, at the Health and Sanitation Service Exhibition Hall of the Shougang Park of the 2021 Service Trade Fair, the staff were introducing protective clothing.
Xinhua News Agency reporter Ren Chao photo
On September 4, at the booth of Beijing Children's Hospital, staff introduced the 5G networked artificial intelligence infant airway management remote early warning consultation system to children.
Photo by Xinhua News Agency reporter Zhang Yuwei
The 2021 China International Service Trade Fair (hereinafter referred to as the "Service Trade Fair") will set up a health service topic for the first time.
This special exhibition includes six themes of epidemic prevention and control, medical services, technological innovation, traditional medicine, elderly health and international medical care, covering areas such as innovative drugs and high-end medical devices.
From September 3rd to 7th, a large number of well-known medical institutions and leading pharmaceutical companies showed innovative products around the theme of "Digital Health Innovation and Integration" at Hall 5 in Beijing Shougang Park.
The special exhibition was also accompanied by 14 forum meetings. Experts in the field of health and health from various countries, medical institutions and leaders of pharmaceutical companies gathered together to give keynote speeches on the future of global health and share new ideas and perspectives.
In addition, the thematic exhibition also set up multiple functional areas such as interactive area, experience area, and contract area. The content is rich, the form is diversified, and China's medical technology innovation level, medical product innovation results, and medical service innovation are displayed to the world from all angles. Competence and quality of health service development have built a global platform for communication, exhibition and cooperation.
Upgraded version of the new crown vaccine, new crown specific drugs, mobile testing laboratories, 5G mobile stroke vehicles, minimally invasive vascular interventional surgery robot "doctors"... At the 2021 Service and Trade Fair, a large number of cutting-edge technologies in the medical and health field have been unveiled, allowing the exhibitors to bear with them Can't help but marvel at the rapid development of China's medical technology.
Now, let us walk into the Service Trade Fair together to get to know these new achievements.
Anti-epidemic weapon boosts public confidence
At the 2020 Service and Trade Fair, the new crown vaccine exhibited by Sinopharm China Biotech has become a "explosive product."
At this service trade fair, China Biotech brought 9 products: 4 new crown vaccines developed by 3 technical routes in the "preventable" field, 3 diagnostic reagents in the "diagnosable" field, and two in the "curable" field Specific drugs (specific immunoglobulin, monoclonal antibodies).
Among them, the second-generation vaccine against mutant strains and two specific drugs are the world's first releases.
At present, the two new crown inactivated vaccines of Beijing Institute of Biological Products and Wuhan Institute of Biological Products have been approved for marketing.
The two COVID-19 inactivated vaccines displayed at the Service Trade Fair are upgraded versions that can effectively neutralize mutant strains.
In addition to inactivated vaccines, China Biotech also displayed recombinant protein new crown vaccines and mRNA vaccines developed for virus variants.
"From the perspective of clinical trials, the recombinant protein new crown vaccine can effectively fight against mutant strains such as Delta. At the same time, the mRNA vaccine with independent intellectual property rights of China Biologics is currently improving its platform construction and large-scale production layout." China Biologics Party Committee Secretary of Sinopharm Group Zhu Jingjin, the global leader of the third phase of the new crown vaccine clinical project, said, "I look forward to this second-generation vaccine against mutant strains as soon as possible to help the world overcome the epidemic as soon as possible."
In addition to effective prevention, treatment for patients with new coronary pneumonia is also very important.
The new crown-specific immunoglobulin exhibited by China Biotechnology recently obtained the "Approval for Clinical Trials of Drugs" issued by the State Food and Drug Administration, and was approved to carry out clinical trials.
This is the world's first new coronary pneumonia-specific drug prepared from plasma after immunization with the new coronary inactivated vaccine, and it is another breakthrough achievement of Sino Biotech in the field of new coronary pneumonia treatment.
Monoclonal antibody, another therapeutic drug, has a neutralizing effect. It can be used as a short-term prevention for high-risk groups as well as for the treatment of diseases after viral infection. It is a hot spot in global research on the prevention and control of the new crown epidemic.
"In fact, China's new crown-specific immunoglobulin has been approved for emergency use and has been included in the "New Coronavirus Pneumonia Diagnosis and Treatment Program" of the Health Commission. It has played an important role in the treatment of critically ill patients with new crowns." Zhu Jingjin said, In terms of "diagnosis, treatment, and prevention", China Biotech has made major breakthroughs, demonstrating Chinese technology, Chinese manufacturing and Chinese power.
Outside the health and sanitation service exhibition hall, a square cabin truck of more than 10 meters is very eye-catching.
This is the “mobile P2+ biosafety inspection vehicle” exhibited by the Beijing Municipal Center for Disease Control and Prevention. It is built in strict accordance with the standards of biosafety laboratories. Separation, cultivation, and testing of biological and other suspected samples can reduce the time of sample circulation and the flow of people to be tested, which is conducive to reducing the prevention and control area, improving the detection efficiency, and adding assistance to the prevention and control of the epidemic.
Medical results respond to people's livelihood concerns
A single heel blood collection can screen for nearly 600 genetic disease risks at one time, and perform a few actions to assess the child's movement development. A set of 5G networking system can realize remote real-time consultation and artificial intelligence navigation decision-making for infant airway management …At this service trade fair, Beijing Children’s Hospital of the National Children’s Medical Center presented 10 innovative projects in one go, of which 6 projects were signed on-site, demonstrating my country’s innovative service level in the field of pediatric medical care.
"This is a closed-loop management system for neonatal screening and clinical application based on targeted sequencing." At the booth of Beijing Children's Hospital, the staff introduced that the system focuses on the practical problems of the tertiary prevention of neonatal birth defects in my country and only needs to take one newborn. The heel blood of a child can be extracted with a trace amount of DNA, which can screen 596 kinds of relatively high-incidence and serious health-related single-gene genetic diseases related to 465 genes, and assess the risk of neonatal disease.
This technology will effectively promote the early screening, diagnosis and treatment of rare genetic diseases in my country.
In the exhibition area of Peking Union Medical College Hospital, two new devices are particularly eye-catching.
According to Liu Shuo, assistant to the director of the Affairs Management Department of the Western Hospital of Xiehe Hospital, one of them is the "ReadyGo", a quantitative assessment system for motor function jointly developed by the Department of Neurology and the Software Institute of the Chinese Academy of Sciences.
The system is based on in-depth visual perception technology, which can complete quantitative analysis of more than ten classic sports tests such as gait test, balance test, and TUG test, and conduct a comprehensive and objective assessment of the motion function of the analyst. "Just take a few steps and know Your gait is correct.” The other is a supportive endoscopy assist system independently developed by the ENT team, which can solve a series of problems such as one-handed operation of endoscopic surgery, blood-stained lenses, and shaking of key operating fields, freeing the doctor's hands.
On the south side of the Health Service Exhibition Hall, an ambulance with "5G Mobile Stroke Unit" is very eye-catching.
Stepping up a few steps into the car, you can see the mobile CT, inspection equipment, monitoring equipment, etc., which can be described as "the sparrow is small, but it has all the internal organs."
Shang Guowei, director of the Office of the National Engineering Laboratory of Internet Medical Diagnosis and Treatment Technology of Xuanwu Hospital of Capital Medical University, introduced that this is a 5G mobile stroke jointly developed by the National Engineering Laboratory of Internet Medical Diagnosis and Treatment Technology of Xuanwu Hospital and jointly developed by China Unicom and Beichuang Power. The unit uses innovative technologies such as the Internet of Things, the Internet, and 5G to connect medical personnel, information, and equipment resources related to stroke first aid to form a patient’s "carriage with experts, experts with tools, tools with platforms, platforms with information, and information for patients The "integrated treatment model", to seize the golden time for treatment for patients, is of great strategic significance for improving the ability of medical institutions to prevent and control major diseases such as cerebrovascular diseases.
Medical innovation to solve the needs of patients
A filament can move forward and backward freely and flexibly in the catheter, which can assist in the completion of minimally invasive vascular interventional surgery, tirelessly and not afraid of radiation.
This is the "robot doctor" for vascular interventional surgery developed by Yidu Hebei Robot Technology Co., Ltd.
According to Chen Yang, the person in charge of the company, traditional vascular interventional surgery is complicated and poorly controllable. It requires rich operating experience, and doctors are often exposed to a lot of radiation during surgery. This vascular interventional robot is the "Minimally Invasive Vascular Intervention Surgery Assistant System". Developed to solve these problems.
"This technology is currently at the leading level in the industry both domestically and internationally." Chen Yang said that compared with traditional surgical operations, the system has reached a higher level of accuracy and stability of device push.
Today, the level of precision and personalized treatment of hematological tumors in China still needs to be improved.
“Take patients with chronic myeloid leukemia with the T315I mutation as an example. At present, many patients in the clinic are waiting for trial and error of standard therapies in the form of'test drugs' after the emergence of drug resistance. This will obviously delay the patient's optimal treatment opportunity." Yang Dajun, Chairman and CEO of Sheng Medicine, said that if the T315I mutation patients can be accurately screened through genetic testing, it will be possible for patients to use innovative drugs earlier and to achieve long-term survival.
At this session of the Service Trade Fair, Yasheng Pharmaceuticals brought the original Class 1 new drug oribatinib.
Speaking of oribatinib, most people may feel confused, but when it comes to its story, many people are very familiar with it-in the movie "I am not the god of medicine", it is used to treat drug-resistant chronic myeloid leukemia (abbreviated as The first-generation drug Gleevec (Imatinib) of CML is called "Gleenin".
It helps patients turn incurable diseases into chronic diseases and can effectively prolong the lives of patients. However, patients will become resistant to long-term medications. Once related genes are mutated, first-generation or second-generation drugs will become ineffective.
Oribatinib, as China’s first third-generation BCR-ABL targeted drug-resistant CML therapeutic drug, targets a variety of BCR-ABL mutants including the T315I mutation, and is known as the “third-generation Gleevec ".
At present, Orebatinib has submitted a new drug marketing application and has been included in the priority review and breakthrough treatment varieties.
"I hope that more patients can use the world's leading original and innovative drugs developed by Yasheng Pharmaceutical to meet their urgent clinical needs." Yang Dajun said.
Wang Meihua